Time filter

Source Type

Nanjing, China

Xu C.-H.,Nanjing Chest Hospital | Yu L.-K.,Nanjing Chest Hospital | Wang Q.-B.,Nanjing Second Hospital
Chinese Journal of Cancer Prevention and Treatment | Year: 2013

OBJECTIVE: To investigate serum receptor-binding cancer antigen expressed on SiSo cells (RCAS1) levels in non-small cell lung cancer (NSCLC)and its clinical significance. METHODS: Patients with NSCLC (n=102)and benign lung disease (n=40) and healthy controls (n=35)were recruited into this study. Serum RCAS1 levels were measured using enzyme-linked immunosorbent assays (ELISA). The results were compared between patients with different tumor stages, metastasis status, and postoperative recurrence 1 year after surgery. RESULTS: Patients with NSCLC had higher RCAS1 levels [(48.6±18.5) U/mL]than that of the benign lung disease [(18.3±14.8) μg/mL; t=3.73, P=0.001] and the healthy group [(13.5±11.8) μg/mL; t=7.56, P=0.000]. Serum RCAS1 levels in stageIII/IVpatients [(60.8±16.3) U/mL] were significantly higher than that of stageI/IIpatients [(34.6±15.3) U/mL; t=3.56, P=0.000]. Serum RCAS1 levels were higher in patients with distant metastasis or postoperative recurrence [(58.3±16.9) U/mL, (59.6±14.9) U/mL]than those without them [(35.6±13.2) U/mL, (33.8±13.6) U/mL; t=3.47, P=0.002; t=5.83, P=0.001]. CONCLUSION: Serum RCAS1 level in patients with NSCLC could be a useful marker for metastasis and postoperative recurrence.

Su J.,Nanjing Southeast University | Zhou Z.,Nanjing Second Hospital | Li H.,Nanjing Southeast University | Liu S.,Nanjing Southeast University
Analytical Methods | Year: 2014

An immunogold chromatographic assay was developed for quantitative determination of human chorionic gonadotropin (HCG) antigen. The monoclonal antibody to beta-HCG antigen (Mab II) conjugated gold nanoparticles (GNPs) were sprayed onto a conjugation pad for specific binding with the target protein to form an immunocomplex. The monoclonal antibody to alfa-HCG antigen (Mab I) was immobilized on the test line (T zone) of the nitrocellulose membrane (NC membrane) to capture the immunocomplex of gold nanoparticle labeled Mab II and HCG protein. Therefore, GNPs would aggregate on the test line of the NC membrane in the presence of HCG, which could be easily distinguished by the naked-eye. As for quantitative detection, the gray value of the red color in the T zone was proportional to the corresponding sample concentration. The gray value versus logarithm concentration curve presented a good linear relationship in the range of 10-600 ng mL-1. The duration of the assay was within 15 min and no professional large-scale analytical instrument was necessary for quantification. When applied in human serum analysis, the strips could reach the requirements of the clinic tests. This journal is © 2014 The Royal Society of Chemistry.

Qian J.,Nanjing Southeast University | Zhou Z.,Nanjing Second Hospital | Cao X.,Nanjing Southeast University | Liu Songqin S.,Nanjing Southeast University
Analytica Chimica Acta | Year: 2010

Here, we describe a new approach for electrochemiluminescence (ECL) assay with Ru(bpy)3 2+-encapsulated silica nanoparticle (SiO2@Ru) as labels. A water-in-oil (W/O) microemulsion method was employed for one-pot synthesis of SiO2@Ru nanoparticles. The as-synthesized SiO2@Ru nanoparticles have a narrow size distribution, which allows reproducible loading of Ru(bpy)3 2+ inside the silica shell and of α-fetoprotein antibody (anti-AFP), a model antibody, on the silica surface with glutaraldehyde as linkage. The silica shell effectively prevents leakage of Ru(bpy)3 2+ into the aqueous solution due to strong electrostatic interaction between the positively charged Ru(bpy)3 2+ and the negatively charged surface of silica. The porous structure of silica shell allowed the ion to move easily through the pore to exchange energy/electrons with the entrapped Ru(bpy)3 2+. The as-synthesized SiO2@Ru can be used as a label for ultrasensitive detection of biomarkers through a sandwiched immunoassay process. The calibration range of AFP concentration was 0.05-30ngmL-1 with linear relation from 0.05 to 20ngmL-1 and a detection limit of 0.035ngmL-1 at 3σ. The resulting immunosensors possess high sensitivity and good analytical performance. © 2010 Elsevier B.V.

Wu Y.,State Key Laboratory of Bioelectronics | Zhou H.,Nanjing Southeast University | Wei W.,State Key Laboratory of Bioelectronics | Hua X.,State Key Laboratory of Bioelectronics | And 3 more authors.
Analytical Chemistry | Year: 2012

Apoptosis is involved in the pathology of a variety of diseases. The measurement of apoptosis will help us to evaluate the onset of disease and the effect of therapeutic interventions. In addition, the increased demand for understanding the early stages of apoptosis is pushing the envelope for solutions in early instance real-time monitoring of death kinetics. Here we present a novel electrochemiluminescent cytosensing strategy to quantitate apoptotic cell numbers, screen some anticancer drugs, and evaluate their effects on hepatocarcinoma cell line (HepG2) cells by utilizing the human antiphosphatidyl serine antibody (APSA) conjugated Ru(bpy) 3 2+-encapsulated silica nanoparticle (APSASiO 2@ Ru) as the detection probe. HepG2 cells were easily immobilized on the arginine-glycine- aspartic acid-serine (RGDS)- multiwalled carbon nanotubes (RGDS-MWCNTs) nanocomposite by the specific combination of RGD domains with integrin receptors on the cell surface. Then APSA-SiO 2@Ru was introduced to the surface of apoptosis cells through the specific interaction between APSA and phosphatidylserine (PS) that distributed on the outer membrane of apoptotic cells. On the basis of the signal amplification of the APSA-SiO2@Ru nanoprobe, the cytosensor could respond as low as 800 cells mL -1, showing very high sensitivity. In addition, the dynamic alterations of surface PS expression on HepG2 cells in response to drugs and the cell heterogeneity were also demonstrated. The strategy presented a promising platform for highly sensitive cytosensing and convenient screening of some clinically available anticancer drugs. © 2012 American Chemical Society.

Xu C.,Nanjing Chest Hospital | Hao K.,Nanjing Chest Hospital | Hu H.,Nanjing Chest Hospital | Yan J.,Nanjing University | And 2 more authors.
Lung Cancer | Year: 2014

Objectives: Enhancer of zeste homolog 2 (EZH2) plays a key role in tumorigenesis and cancer progression through epigenetic gene silencing and chromatin remodeling. The objective of this study was to investigate the correlation between EZH2 expression and platinum-based chemotherapy response as well as survival of patients with advanced non-small cell lung cancer (NSCLC). Materials and methods: We identified 360 consecutive stage IIIB and IV NSCLC patients who underwent first-line platinum-based chemotherapy. Immunohistochemical analysis of EZH2 on the paraffin-embedded pre-treatment tumor samples was performed and correlated with chemotherapy response and survival. Results: EZH2 was positive in 204 of 360 patients (56.7%). Of the 204 positive EZH2 patients, 72 (35.3%) responded to chemotherapy with either complete response, or partial remission. Of 156 negative EZH2 patients, 90 (57.7%) exhibited a response to chemotherapy. The difference in response to therapy between positive and negative EZH2 patients was statistically significant (. p<. 0.01). Univariate survival analysis indicated that patients with positive EZH2 had a significantly lower disease-free survival (DFS) and overall survival (OS) than those patients with negative EZH2 expression. Multivariate Cox regression analysis demonstrated that positive EZH2 expression was an independent prognostic factor for both DFS and OS. Kaplan-Meier survival curves further confirmed that positive EZH2 expression correlates with poor survival in NSCLC patients. Conclusions: Our results indicate that advanced NSCLC patients with positive expression of EZH2 exhibited resistance to cisplatin-based chemotherapy. EZH2 may be a predictive and prognostic factor for cisplatin-based therapy response and disease survival in advanced NSCLC. © 2014 Elsevier Ireland Ltd.

Discover hidden collaborations